Docket No. FDA-2015-D-0198: Current Good Manufacturing Practice Requirements for Combination Products.
|
|
- Junior Norris
- 6 years ago
- Views:
Transcription
1 701 Pennsylvania Avenue, Ste. 800 Washington, DC Tel: Fax: April 29, 2015 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD Re: Docket No. FDA-2015-D-0198: Current Good Manufacturing Practice Requirements for Combination Products. Dear Sir or Madam: The Advanced Medical Technology Association ( AdvaMed ) is pleased to provide comments on FDA s draft guidance Current Good Manufacturing Practice Requirements for Combination Products. AdvaMed represents manufacturers of medical devices, diagnostic products, and health information systems that are transforming health care through earlier disease detection, less invasive procedures, and more effective treatment. Our members range from the smallest to the largest medical technology innovators. Generally speaking, industry is encouraged that FDA devised a streamlined program intended to assist manufacturers in complying with 21 C.F.R. Part 4. We have, however, a number of significant issues with the guidance and, importantly, the draft guidance does not sufficiently answer many questions concerning how best manufacturers can comply with this regulation. Our specific comments on the draft guidance are provided in the attachment. We also attached a line-numbered version of the draft guidance to facilitate your review. General thoughts about the draft guidance are provided below. The guidance should make clear that Part 4.4. (e) is intended to apply exclusively to the dual system and that for a streamlined system, companies should incorporate the streamlined provisions required and then determine for themselves how to ensure that the underlying SOPs in place appropriately address the quality requirements for drug or device constituent part, rather than seeking the most stringent regulation cited in either Part 820 or part 211. This is supported by section Part 4.4. (e) of the final rule, which states that,... in the event of a conflict between regulations applicable under this subpart to combination products, including their constituent parts, the regulations most specifically applicable to the constituent part in question shall supersede the more general. This provision is discussed in the preamble only in the context of a system that
2 Docket No. FDA-2009-N-0435 April 29, 2015 Page 2 of 20 incorporates both drug and device CGMPs [ Specifically, this commenter sought guidance on how to resolve conflicts among requirements of the regulations applicable to a combination product if implemented in accordance with 4.4(a)(1). ] and should be included in the text of the guidance document. The draft guidance states that this discussion is not meant to be a comprehensive analysis and then essentially repeats the regulations almost verbatim (in terms of the QS regulation-based streamlining approach Section IV.B). It would be helpful if the guidance provided a more comprehensive discussion on interpretation of specified additional provisions under the streamlined approach, including flexibility in interpretation and acceptable documentation of compliance. Some of the comments in the attached table identify additions or clarifications to the guidance that could inform manufacturer s routes to compliance. The draft guidance, in section IV.B.6 Stability Testing, only mentions a written testing program; however, it fails to discuss the differences and requirements for primary stability programs designed to meet registration expectations and annual stability programs designed to monitor the stability of the drug product over its commercial lifetime. More guidance to this point is needed. Thank you for the opportunity to submit comments on this draft guidance document. Respectfully submitted, /s/ Sharon A. Segal, Ph.D. Vice President Technology and Regulatory Affairs Attachment 2
3 ADVAMED COMMENTS Good Manufacturing Practice Requirements for Combination Products Strikeout = deleted text Underline = suggested new text Line # Change Reason & 67 Revise to add the following at the end of this sentence: The final rule does not establish any new requirements Revise to read as follows: as to further inform Editorial change Revise to read as follows: Instead, this guidance describes Editorial change (Footnote 2) Add the page range to incorporate entire content of FR notice Revise to read as follows: but is not required Editorial change Specify whether there can be an accessory to a combination product and how it would be regulated. Revise to read as follows:... streamlined approach, demonstrating full compliance with either the drug CGMPs.... Revise to read as follows: The complete drug and the following provisions from the QS regulation in accordance... Revise to read as follows: The complete QS regulation and the following provisions from the drug CGMPs in accordance Include the CGMP regulation for Biologics/HCT/P) Revise to read as follows: Regardless, manufacturers should consider how to manage internal documentation need to demonstrate compliance with all any applicable CGMP requirements of the constituents (Device, drug) and should consider how to manage internal documentation to demonstrate compliance. To ensure the reader understands that there are no new regulatory requirements being added for Combinations Products, i.e., as stated by Federal Register Vol 78(14), January 22, 2013, p.4318, Comment 28 Response To ensure the reader understands all of the FDA viewpoints in comment/ FDA response. Clarification. The guidance provides no discussion on accessories of the specific constituent devices or accessories to the combination product (CP) itself. Clarification Clarification consistent with 21 CFR 4.4(b)(1) Clarification consistent with 21 CFR 4.4(b)(2) Revision for clarity as drugs and devices are mentioned, but not biologics etc., and the last sentence of this paragraph mentions 21 CRF 4.4(b). As written, this can be interpreted to mean that only the 6 device sections or only the 8 drug sections listed in lines need to be implemented for the streamlined approach. Discussions with FDA have indicated there is an expectation that the base quality system must already address those CGMP sections not listed. For example, while CAPA is not listed, a drug manufacturer is expected to have a compliance CAPA system already in place as part of their base quality system. 3
4 ADVAMED COMMENTS Good Manufacturing Practice Requirements for Combination Products Line # Change Reason Revise to read as follows: To facilitate efficient inspection, the agency recommends that manufacturers who choose to operate under a streamlined approach clearly identify in their premarket submissions and at the initiation of an inspection whether they are operating under the drug CGMP-based or QS regulation-based streamlining approach. For products for which the premarket submissions were made prior to promulgation of 21 CFR part 4, such manufacturers should clearly identify at the initiation of an inspection whether they are operating under the drug CGMPbased or QS regulation-based streamlining approach. Specify where this information should be provided in a Common Technical Document (CTD) dossier and/or Standard Technical Document (STED). Recommend that this be provided as a stand-alone Module 1 or Regional CTD that can then be provided during an audit. Similarly this approach could be taken within the format of a DMF or appropriate submission. Further clarify Primary Mode of Action (PMOA): criteria and responsibilities for determination; responsibilities and process for resolving discrepancies between the sponsor and the Agency regarding PMOA. Revise to read as follows: Manufacturers must demonstrate that each applicable CGMP requirement is complied with for the corresponding constituent parts and the combination product, if appropriate. Revise to read as follows: If a streamlined approach is used, the manufacturer must demonstrate compliance with all of the relevant provisions of either the drug CGMPs or QS regulation, and the provisions specified in 21 CFR 4.4(b) for the other set(s) of CGMP requirements applicable to its product. A manufacturer that chooses to use the streamlined approach is not required to comply with the other specific GMP/QSR requirements, beyond those specified in 21 CFR 4.4(b). The draft generally does not give much guidance about legacy products. In this sentence, it does not take into account that indicating the use of a streamlined approach in a premarket submission is not possible for a legacy product. Clarification. Clarification on the PMOA and how it is determined for a new type of combination product would be helpful in this section. Clarification Revise to read as follows:... applicable to its the product Clarification It should be emphasized that all other requirements as stated in the QSR/CGMPs rule do not need to be followed in a streamlined approach. [Federal Register Vol 78(14), January 22, 2013, p , I. Background, (B) The Proposed Rule and (C) The Final Rule]. Although the examples are helpful, the current draft does not state clearly enough that the provisions in 21 CFR 4.4(b) would be sufficient to achieve compliance and additional requirements of the other QSR/CGMP do not apply. A manufacturer would have to consider whether other requirements of the drug GMP are also applicable. 4
5 ADVAMED COMMENTS Good Manufacturing Practice Requirements for Combination Products Line # Change Reason Section C.4.2 Definitions Section C.4.2 Definitions Add the following definition to this section: Reserve Sample [ ]: An appropriately identified reserve sample that is representative of each lot in each shipment of each active ingredient shall be retained. [ (a)] An appropriately identified reserve sample that is representative of each lot or batch of drug product shall be retained and stored under conditions consistent with product labeling. The reserve sample shall be stored in the same immediate container-closure system in which the drug product is marketed or in one that has essentially the same characteristics. [ (b)] Reserve samples are needed to help ensure the postmarket safety and effectiveness of combination products. They are used, for example, to address certain product complaints, evaluate stability concerns, and assess the causes of adverse events. Add the following definition to this section: Retained Sample[ (d)]: A representative sample of each lot of (bulk drug) component [ (1)] A representative sample of the Final Combination Product (Drug product) per appropriate (representative sample) criteria [ (2)] Representative Sample/Surrogates A representative sample of a combination product which has a PMOA as a device, does not have to be an actual finished device. The manufacturer may develop a surrogate product that would meet the intent of the regulations. to help ensure the postmarket safety and effectiveness of combination products. They are used, for example, to address certain product complaints, evaluate stability concerns, and assess the causes of adverse events. Examples of potential surrogates include but are not Reserve and Retained Sample terminology is confusing and contradictory. As the FDA guidance s purpose stipulates it is to help device manufacturers, this is an important concept FDA Guidance line ; This discussion is not meant to be a comprehensive analysis, but rather to help manufacturers particularly device manufacturers, who may be less familiar with the drug CGMPs understand the purpose and basic content of the specified provisions of the drug CGMPs, as well as where to find additional guidance. Reserve and Retained Sample terminology is confusing and contradictory. As the FDA guidance s purpose stipulates it is to help device manufacturers, this is an important concept FDA Guidance line ; This discussion is not meant to be a comprehensive analysis, but rather to help manufacturers particularly device manufacturers, who may be less familiar with the drug CGMPs understand the purpose and basic content of the specified provisions of the drug CGMPs, as well as where to find additional guidance. 5
6 ADVAMED COMMENTS Good Manufacturing Practice Requirements for Combination Products Line # Change Reason limited to: o o Sections of a catheter that was extruded, coated and packaged in the same manner as the finished product Extruded catheters without electronics included. When using a surrogate sample, the manufacturer must maintain documentation demonstrating that the surrogate will meet the intent of the regulation, to help ensure the postmarket safety and effectiveness of combination products. They are used, for example, to address certain product complaints, evaluate stability concerns, and assess the causes of adverse events. Manufacturers are encouraged to use the least burdensome method necessary to demonstrate compliance with this section of the regulation. Note that as a Reserve Sample will be retained, a Retained Sample may be reserved, i.e., 21 CFR and may fulfill the same function [21 CFR (b); 21 CFR ]. Add the following to the Manufacturer definition: CFR 134.1(b) Country of origin. Country of origin means the country of manufacture, production, or growth of any article of foreign origin entering the United States. Further work or material added to an article in another country must effect a substantial transformation in order to render such other country the country of origin within the meaning of this part; however, for a good of a NAFTA country, the NAFTA Marking Rules will determine the country of origin. A sentence stating that the final rule does not alter existing requirements for establishment registration should be added. For example, implementing Design Controls related to the device constituent of a drug-device or biologic-device Combination Product at an existing drug establishment (or any other facility owned by a drug or biologic manufacturer / sponsor) should not impose a requirement to also register those facilities as device establishments (specification developers) 6 FDA Manufacturer definition does not incorporate a reference to US Customs 19 CFR 134 manufacturer definition in relation to Country of Origin In consideration of package labeling and potential Combination Products components from outside the USA, Customs definition takes priority, i.e.,: 19 CFR , Requirements of other agencies; Nothing in this subpart shall be construed as excepting any article (or its container) from the particular requirements of marking provided for in any other provision of any law, such as those of the Federal Trade Commission, Food and Drug Administration, and other agencies. The lines referenced state that any facility that conducts design activities is a manufacturing facility. While this statement appears to be consistent with the definition of manufacture as provided within 21 CFR Part 4, there is a concern that that this statement could be misinterpreted to imply that a facility registered as a drug establishment is now also required to register as a device establishment if that facility implements Design Controls related to the device constituent of a
7 ADVAMED COMMENTS Good Manufacturing Practice Requirements for Combination Products Line # Change Reason because they are not designing finished medical devices for distribution. Rather, they are designing medical device constituents to be incorporated into a drug-device or biologicdevice Combination Product. Regarding the specific case of design centers that are remotely located from a drug manufacturer s registered drug establishment they would, heretofore, not have been required to register as a drug establishment. Therefore, the guidance should be clear that the new rule does not impose a new requirement that they now register as device establishment(s). Revise to read as follows:....device component (not a finished device) per 21 CFR Part 820.3(c) and is not otherwise subject to the QS regulation... Revise to read as follows:... for a combination product solely because of 21 CFR Part 4. Revise to read as follows: demonstrate compliance with both the drug CGMPs and QS regulation per applicability of Sec 4.4. The guidance addresses Class I liquid medication dispensers appropriately (as non-drug contacting and drug contacting), however there are Class II/Class III devices that are similarly packaged (e.g., disposable pre-packaged, pre-sterilized syringes in their manufacturer s packaging). The guidance is not clear if these devices would be considered convenience kit devices not subject to additional CGMPs by the kit manufacturer (e.g., for a vial packaged with a packaged syringe and needle) The guidance should state additional conditions or examples including Class II/Class III devices. Revise to read as follows: If such a liquid medication dispenser is co-packaged with a drug as a convenience kit (see III.C.4 below), generally speaking no additional CGMP requirements would apply to that dispenser or to the combination product under part 820 simply because that dispenser is included in the kit. Note, however, that a device constituent part incorporated into a drug container Combination Product. Similarly, there is concern that any facility that a drug manufacturer might use to support the design and development of the device constituent in a drug-device or biologic-device Combination Product (e.g., headquarter facility, satellite design center, laboratory etc.) is required to register that facility as a device establishment (specification developer). If the agency is of the view that the publication of the final rule somehow alters requirements with respect to facility registration for manufacturers of a Combination Product, it should revise existing laws and rules related to device, drug, biologic or Human Cellular Tissue Products (HCT/P) for establishment registration. Failing that, the guidance should be explicit as to what the requirements are so as to avoid industry confusion. Clarification. Provided reference from regulation to define a component. Clarification Clarification Clarification. Suggestions to bring clarity to the overall statement regarding simple low risk devices. The Agency is urged to consider providing additional definition regarding simple devices. The combinations suggested to be added are simple, much like an oral dosing cup; however, in many cases, they are not classified or they are components until the point in time where they are combined with the 7
8 ADVAMED COMMENTS Good Manufacturing Practice Requirements for Combination Products Line # Change Reason raises additional considerations. For example, when establishing batch testing and release and product stability testing criteria under 21 CFR and , a dropper incorporated into a drug container s cap would need to be addressed as part of the drug container because it would come into contact with the drug product. Similarly, when such a dropper is used in conjunction with the drug, the dropper may need to meet certain specifications for dosing of the specific drug product or for maintaining its integrity while in contact with the drug product, for example. As a result, design controls specific to the use of the dropper and its contact with the drug product may be needed and apply under 21 CFR It is understood that appropriate quality controls must be applied to a class 1 device constituent part incorporated into a drug container according to the intended use. For example, Under 21 CFR and , a dropper incorporated into a drug container s cap that is part of the primary container closure system during product release testing and within the packaged product stability program. Measuring devices (i.e. droppers, design cups, etc.) used in conjunction with drugs, should be calibrated to assure dose accuracy. Measuring devices (i.e. droppers, design cups, etc.) used in conjunction with drugs must be evaluated to assure safety, suitability, compatibility with the product. As a result of the above, design controls specific to the use of the dropper and its contact with the drug product are not needed and do not apply under 21 CFR , since other controls are in place to assure quality. It is recommended that the Guidance include discussion and examples for other simple devices that may be used in combination, such as an integrated spray nozzle or pump for OTC nasal products, pumps that deliver topical drug products, pads or sponges that are used to apply cosmetics that contain a sunscreen, etc Revise to read as follows:... a kit that includes two or more different types of medical products container closure of the drug to create the combination product. These are traditionally low risk and should follow a similar logic as defined for the liquid medication dispensers described in lines of the guidance document. The Agency should consider appropriate risk analyses in making these recommendations. Clarification 8
9 ADVAMED COMMENTS Good Manufacturing Practice Requirements for Combination Products Line # Change Reason Footnote 14 ( ; ) Revise to read as follows: 2) included in the kit as already offered as a finished device or packaged for independent marketing and with the same labeling as required for independent marketing Reference the Convenience Kits Interim Regulatory Guidance. Add a sentence that stresses that a sponsor (manufacturer of CP) should assess every constituent of the CP (for QS based approach and/or Drug CGMP approach) independently and see what CGMP requirements apply to the constituent if separately marketed (e.g., servicing, installation, cleanroom and other QSR regulations that may not be applicable to the device constituent). Add the following to the end of this section: Furthermore, the preamble to the final rule addressed the requirement differences based on antimicrobial-antibiotic related combination products intended use, e.g., verification and quantitative testing of antimicrobial activity could be a suitable surrogate for the determination of strength if the antimicrobial coating serves only to inhibit or prevent microbial colonization of the device, but qualitative testing would not be appropriate. Clarify designation of Legal Manufacturer, place of manufacture on the labeling, and also for custom and import/export purposes. Add additional information regarding post market data/complaint data into the applicable CGMP systems operated at different facilities. Revise to read as follows: The combination product sponsor 17 is responsible for ensuring that the manufacturing activities for its product occurring at all facilities, including facilities operated by third parties, are in compliance with CGMP requirements. This responsibility is fulfilled by the medical product manufacturer through traditional Some Class 1 devices for oral drug delivery or other devices do not always require secondary packaging and may be packed in a convenience kit with only their surfaces appropriately labeled. Secondary packaging for these devices should not be a necessary condition for them to meet the definition of a convenience kit. Clarification nce/guidancedocuments/ucm htm Clarification Federal Register Vol 78(14), January 22, 2013, p.4316, Comment 24 Response Maybe an oversight of FTC, not FDA; but need to reach a common ground. Place of substantial transformation vs PMOA. Clarification Although the manner in which a manufacturer might exercise control over a third party is covered later in the draft, there is no explicit indication that these controls constitute the full extent of the manufacturer s responsibility. In other words, the application holder is responsible for the CGMP/QSR compliance and the 3 rd party manufacturer is responsible for complying with the 9
10 ADVAMED COMMENTS Good Manufacturing Practice Requirements for Combination Products Line # Change Reason means, such as quality agreements and audits, as outlined below. This Guidance does not intend to create additional means of supplier quality controls other than those already required by CGMPs and the QSR. Revise to read as follows: Even if a facility is manufacturing only one type of constituent part for a combination product, the CGMP operating system should take into consideration the combination product as a whole, as appropriate. However, if the constituent part is intended for general purpose use or a specific indication it is not the obligation of the combination product manufacturer to include another manufacturer s use in the development in that constituent part. Clarify whether testing refers to the combination product or the constituent. Revise to read as follows:... that might arise from changes to the product or any constituent part of the product Revise to read as follows:: The manufacturer should also establish procedures for acceptance of components, containers/closures, and constituent parts to ensure both detection and evaluation of any changes that are critical to the safety and effectiveness of the combination product prior to incorporating them into the finished combination product. Revise to read as follows: All such controls should be designed to reduce, eliminate, or ideally, prevent qualify nonconformities ensure quality of the finished product Revise to read as follows: As specified in the final rule, design controls apply to any combination product that includes a device constituent part, unless exempted under the appropriate classification regulations. application holder s quality agreement. This does not seem necessary. For example, a device component manufacturer does not typically have the experience to include inputs related to drugs/biologics. They rely on the combination product manufacturer for guidance. Clarification of what is being tested Clarification Manufacturers need to have agreements in place with contractors regarding change notification. This is covered in previous lines. However, it is not always possible to inspect components, containers/closures and constituent parts to detect and evaluate changes that are critical to the safety and effectiveness of the product. For example, a material change to a closure or component that is not readily observed unless conducting physical property tests. By keeping this sentence more generic, it eliminates confusion between the CGMP requirements and other processes such as lean six sigma functions. On Lines , the guidance states that certain Class I devices are exempt from certain device GMPS including design controls 10
11 ADVAMED COMMENTS Good Manufacturing Practice Requirements for Combination Products Line # Change Reason Revise to read as follows: Guidance for industry on pharmaceutical development addresses product design and development procedures, reflecting quality by design principles. An approved, documented International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Q8 Quality by Design system that is supplemented by the relevant sections of Design Control is an acceptable approach to meet the Design Control requirements. Compliance with Q8 is acceptable as meeting the Design Control requirements for the drug constituent of a combination product. For many Combination Products where the PMOA is Drug, the device constituent design control requirements can be addressed by ICH Q8 with appropriate additions from 21 CFR ICH Q8 was design to meet the intended uses of the product Add reference to (c). Reference Design Inputs from 21 CFR Part Revise to read as follows and expected product users needs of product users and patients Include additional detail regarding approvals Revise to read as follows: for its intended use, under actual or simulated use conditions. Add additional information regarding design inputs, design outputs, verification and validation procedures in a consistent manner regarding design reviews and approvals to stay consistent between paragraphs. Revise to read as follows:... requires that the manufacturer complete perform risk analysis... Clarification. Per (c), (d), (e), (f), etc. The approval, including the date and signature of the individual(s) approving the requirements, shall be documented. Clarity for Verification vs. Validation See 21 CFR 820.3(aa) (f) Provide correct reference See 21 CFR 820.3(z)(2) (g) Provide correct reference Footnote Number 32 needs to be made into a superscript Editorial change Include reference to FDA guidance on software validation This paragraph mentions Design Transfer for the first time. Include reference to Design Transfer (21 CFR (h) in the reference as a footnote. Clarification. Make the paragraphs regarding design input, output, verification, validation follow a consistent explanation of approvals, documentation in the DHFs, etc. Clarification. Risk Analysis is a continuous process. Clarification nce/guidancedocuments/ucm htm Clarification 11
12 ADVAMED COMMENTS Good Manufacturing Practice Requirements for Combination Products Line # Change Reason Revise to read: should address all the design issues Footnote Revise to read as follows: In addition, the combination product manufacturer must assess the impact of design changes and comply with design control requirements for any modifications that need to be made to a constituent part for use in the combination product (e.g., new formulation of the drug or new features of a device) under 21 CFR (i). Include reference to ISO for risk. Revise to read as follows: 21 CFR details describes how to sample, test, examine... Revise to read: All discrepancies in yyield discrepancies outside of expected documented variation should be investigated. Clarify whether/how automated equipment must be validated and cite Reference Process validation guidance. The term all is too inclusive and implies potentially exhaustive theoretical issues. There are many instances where a minor change to the device or the drug does not affect the safety or the efficacy of the constituents nor the combination product. There are many modifications to drugs that would not affect the combination, so a design control for drug modifications that do not affect the device or the combination product is not necessary. Clarification 21 CFR does not detail these processes, it merely describes them. Current text is too restrictive and implies that any yield calculation that is not exactly the same will require investigation. There is always some amount of normal expected variation in yield. Clarification df Revise to read as follows: Yield determinations must be made at the conclusion of each appropriate phase of manufacturing, processing, packaging, and holding for the drug constituent part(s) and for the combination product as a whole. The device constituent parts before incorporation into the combination product are not required to yield determinations. Accordingly, calculation of yield should be determined at each phase at which component, in-process material, or product loss may occur, during the formulation of the drug prior to incorporation into the combination product, during incorporation (e.g., filling or coating), and during the packaging process. Revise to read:... and the data generated for the yield calculation in a manufacturing or production record should be documented along with the expected yield variation. Clarify when yield determinations begin to apply to the device constituent. Also, require clarification as to whether the yield determinations of the device constituent parts are required before they are incorporated into the combination product. Need to introduce the concept of normal variation for yield. This concept was discussed and agreed to during the May 21, 2014 meeting between FDA and AdvaMed. 12
13 ADVAMED COMMENTS Good Manufacturing Practice Requirements for Combination Products Line # Change Reason (Footnote 54) Revise to read as follows: tamper-evident packaging and labeling alerting to alert customers regarding potential compromises to the product packaging. Clarify that the co-packaged entity retains its own expiration dating within its labeling inside the packaged CP. Revise to read as follows: Laboratory testing must be performed on every batch of a single-entity combination product or surrogates and of the drug constituent part(s) of a copackaged combination product, Revise to read as follows: See 21 CFR 4.3, 4.4, and In addition, under the design control requirements, testing must be performed to demonstrate that the device functionality (i.e., mechanical performance of the device constituent part) is maintained until the specified expiration date. See 21 CFR This device functionality testing can be demonstrated during development only, if adequately studied and justified. Add a discussion that a single entity combination product, not pyrogen-labeled but provided sterile, and that is sterilized via a validated sterilization cycle within the device quality systems (21 CFR 820), may be the more applicable requirement. Revise to read as follows: Specifically, 21 CFR (a) requires appropriate laboratory testing of drug products purporting to be sterile. Depending on the development, validation and control of these processes, appropriate laboratory testing for each batch might include reading dosimeters or recovery of biological indicators. For example, a single entity product that is terminally sterilized via a validated sterilization process according to recognized international standards do not require product testing for Clarification Alert is for potential breaches/compromised packaging and not to protect the features as such. Clarification For individualized serialized combination products, such as cardiac rhythm management leads, single-entity combination product batches do not exist. Therefore, surrogate testing of the drug product is essential to assure that each batch of drug product meets the appropriate acceptance criteria and specifications. Clarify whether testing of the device functionality requires realtime testing for each lot put on annual stability, or if the testing to demonstrate device functionality until expiry can be demonstrated during development of the combination product rather than on each lot of the combination product put on stability in the stability program. For combination product families with large drug portfolios, the amount of repetitive motion required for technicians to test these products throughout a typical ICH drug product stability program would be excessive and unnecessary if well designed studies were performed to support the device throughout the shelf life of the combination product platform. See: Federal Register Vol 78(14), January 22, 2013, p.4314, Comment 18 Response. Additionally, this modified text links to the proposed updates for lines Sterility test such as that described in USP <71> is not appropriate and not recommended for products that are terminally sterilized. Manufacturing processes controlled per the cgmps and achievement of critical validated sterilization process parameters will demonstrate achievement of the defined sterility assurance level. 13
14 ADVAMED COMMENTS Good Manufacturing Practice Requirements for Combination Products Line # Change Reason release. Dosimeters placed during irradiation or biological indicators placed during ethylene oxide or steam sterilization may be used to release the product after terminal sterilization. Revise to read as follows: Special testing may be required for the drug constituent part, or the combination product as a whole, depending on the product. With respect to 21 CFR (a), batch testing requirements would apply both to the drug constituent part and to the finished combination product for a single-entity combination product (such as a prefilled syringe) to ensure the combination product is sterile and pyrogen-free when distributed. For terminally sterilized products, sterility test requirements may be met utilizing dosimetric and parametric release (e.g. sterilization validation). Revise to read as follows: The requirements related to sterility and non-pyrogenicity of the empty syringe would be addressed through compliance with process controls under 21 CFR part 211 and the provisions of 21 CFR part 820 specified in 21 CFR part 4 (for example, design control requirements under 21 CFR and purchasing control requirements under 21 CFR ), rather than batch testing under 21 CFR (a). 56 Additionally, for a single entity combination product, which is labeled sterile but which is not labeled pyrogen-free, and the combination product is sterilized via a validated sterilization cycle within the device quality systems (21 CFR 820), this validated sterilization cycle testing may be considered the appropriate laboratory testing required by 21 CFR (a). Devices and drugs have a long history of effectively applying Sterile Parametric practices. This option should be considered/ USP <1222> acknowledges the limits of sterility testing and the process for utilizing parametric release for drug products. Similarly this is covered for devices under ISO 11135, ISO & -2, ISO , and ISO It might also be recommended that the guidance include as a reference USP 38 <1222> Terminally Sterilized Pharmaceutical Products Parametric Release This is an Agency accepted practice under 21 CFR for the elimination of batch-specific sterility testing. As described in Federal Register [Vol 78(14), January 22, 2013, p.4314, Comment 18 Response], i.e., FDA specifically states that... these provisions essentially call for following whichever requirement is more specifically applicable [4.4e]..... which regulation addresses a manufacturing issue most precisely and which requirement arises from the regulation most specifically applicable to the constituent part..... (FDA) intend to address them in guidance. Thus, for single entity combination product, which is labeled sterile but which is not labeled pyrogen-free, and the combination product is sterilized via a validated sterilization cycle within the device quality systems (21 CFR 820), this validated sterilization cycle testing may be considered: The appropriate laboratory testing required by 21 CFR (a), and The more specifically applicable regulation, and The requirement most specifically applicable. Thus, this particular situation should be addressed in the FDA guidance 14
15 ADVAMED COMMENTS Good Manufacturing Practice Requirements for Combination Products Line # Change Reason , 1180, 1595 Revise to read as follows: Accordingly, as explained below, for co-packaged combination products, manufacturers should maintain samples of the drug constituent part, and for single-entity combination products, they should maintain samples that include the device constituent part or components thereof as appropriate. When choosing components or equivalent from a device constituent as the reserve samples containing the drug constituent part, a scientific rationale must be included. Reserve Samples Separate the text s discussion (and requirements for) the two different items: First discuss Active Ingredient (AI) requirements [21 CFR211.84(d)(1)], and then Separately discuss the Drug Product requirements [21 CFR211.84(d)(2)] (Add after L1180): Section D, an antibiotic coated catheter (ACC) example, which utilizes antimicrobial coating to only inhibit or prevent microbial colonization of the device (i.e., not intended to treat infections), focuses on how to comply with the drug CGMP provisions specified in 21 CFR 4.4(b)(2), for example, 21 CFR Yield Calculations to highlight an issue not raised in the previous examples. Considering that the antimicrobial inhibitory function is intended only to inhibit or prevent microbial colonization of the device (i.e., not intended to treat infections), Yield Calculations may be conducted utilizing different measurement techniques. As Yield is a measure of the active ingredients inhibitory strength, and 21 CFR 210(a)(16) defines Strength as: (i) The concentration of the drug substance (for example, weight/weight, weight/volume, or unit dose/volume basis), and/or (ii) The potency, that is, the therapeutic activity of the drug product as indicated by appropriate laboratory tests or by adequately developed and controlled clinical data There are many devices where a Retain Sample of the entire combination could be cost prohibitive and unnecessary to achieve the intent, however when only considering a part of the combination product, a rationale for this should be generated. Provide clarity and reduce confusion between the two distinct reserve sample types. Additionally, the 21 CFR (d) separates these two requirements into (1) and (2), demonstrating their differences. Add an additional Combination Product example where an inhibitory antibiotic coating products antimicrobial activity s verification and quantitative testing is utilized as a suitable surrogate for the strength determination, i.e., a specific CGMP consideration relating to CGMP provisions specified in 21 CFR 4.4(b). The current Drug Coated Mesh Example only describes drug which treats infections, it does not cover the common Combination Product where an antimicrobial coating/ combination product serves only to inhibit or prevent microbial colonization of the device. Based on 21 CFR Yield Calculation related subsections, the yield calculation: May provide valuable information and insight to the status of a manufacturing process at significant evaluation points, not just for the final product. Provides an important quality check both for a pharmaceutical production process as a whole and for individual unit operations of the process. Requires a prompt and thorough investigation when any increase or decrease in expected yield occurs. 15
16 ADVAMED COMMENTS Good Manufacturing Practice Requirements for Combination Products 72. Line # Change Reason 1167, 1180, 1595 (expressed, for example, in terms of units by reference to a standard). Potency measures the functional antimicrobial activity by utilizing an appropriate quantitative zone of inhibition (ZOI) measurement technique. Thus, the Yield Calculations, including Theoretical Yield [ 210(a)(17)], Actual Yield [ 210(a)(18)], Percentage of theoretical yield [ 210(a)(19)], may utilize quantitative zone of inhibition data for their calculation. One acceptable zone of inhibition (ZOI) test method which can be conducted utilizing the actual antibiotic treated material, is Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard Eleventh Edition. M02-A11, Vol 32(1), Clinical and Laboratory Standards Institute, January 2012 However, an appropriate zone of inhibition (ZOI) test method can be conducted utilizing the actual antibiotic treated material, e.g., Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard Eleventh Edition. M02-A11, Vol 32(1), Clinical and Laboratory Standards Institute, January 2012 As the FDA Guidance [line 1167] stated, examples are to focus on specific CGMP considerations relating to CGMP provisions specified in 21 CFR 4.4(b)., and.... [Line 1181] intended to highlight only certain issues that a combination product might raise, and considerations for addressing them, relating to the CGMP provisions specified in 21 CFR 4.4(b). The FDA Federal Register Notice clearly describes cgmp differences for antimicrobial coatings which serve only to inhibit or prevent microbial colonization, a function which is significantly different from the current Drug Coated Mesh example treating infections, [Federal Register Vol 78(14), January 22, 2013, p.4316, Comment 24 Response] Based on 21 CFR Yield Calculation related subsections, the yield calculation: May provide valuable information and insight to the status of a manufacturing process at significant evaluation points, not just for the final product. Provides an important quality check both for a pharmaceutical production process as a whole and for individual unit operations of the process. Requires a prompt and thorough investigation when any increase or decrease in expected yield occurs The Federal Register Vol 78(14), January 22, 2013, p.4316, Comment 24 Response stipulates that: (R)egarding the issue of whether verification and testing of antimicrobial activity could be a suitable surrogate for the determination of strength, we note that it would not be appropriate to use a qualitative activity determination (such as a determination of general antimicrobial activity) in place 16
17 ADVAMED COMMENTS Good Manufacturing Practice Requirements for Combination Products Line # Change Reason 1167, 1180, , 1180, 1595 Add Text (Add after L1595): D. Antibiotic-coated catheter (ACC) 1. Scenario Description Manufacturer A develops an antibiotic coated catheter (ACC) which utilizes antimicrobial coating to only inhibit or prevent microbial colonization of the device (i.e., not intended to treat infections). The primary mode of action is that of a device. This example focuses on how to comply with the drug CGMP provisions specified in 21 CFR 4.4(b)(2), for example, 21 CFR Yield Calculations to highlight an issue not raised in the previous examples. 2. Compliance with drug CGMP requirements different from those described in previous examples; The ACC is a single-entity combination product as defined in 21 CFR 3.2(e)(1) and, therefore, is subject to both the drug CGMPs and device QS regulation. As a device manufacturer, Manufacturer A already has a CGMP operating system designed to comply with the QS regulation and has elected to establish a QS regulation-based CGMP operating system for of a quantitative determination of biological activity (such as a determination of microbial inhibitory concentration (MIC)..... if the antimicrobial coating serves only to inhibit or prevent microbial colonization of the device, then an antimicrobial preservative effectiveness test might be more appropriate Considering that Minimum Inhibitory Concentration (MIC) testing is utilized for varying doses of drug solutions, it would not be appropriate for antimicrobial coated devices. However, an appropriate zone of inhibition (ZOI) test method can be conducted utilizing the actual antibiotic treated material, e.g., Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard Eleventh Edition. M02-A11, Vol 32(1), Clinical and Laboratory Standards Institute, January 2012 The Federal Register Vol 78(14), January 22, 2013, p.4316, Comment 24 Response stipulates that: (R)egarding the issue of whether verification and testing of antimicrobial activity could be a suitable surrogate for the determination of strength, we note that it would not be appropriate to use a qualitative activity determination (such as a determination of general antimicrobial activity) in place of a quantitative determination of biological activity (such as a determination of microbial inhibitory concentration (MIC)..... if the antimicrobial coating serves only to inhibit or prevent microbial colonization of the device, then an antimicrobial preservative effectiveness test might be more appropriate Considering that Minimum Inhibitory Concentration (MIC) testing is utilized for varying doses of drug solutions, it would not be appropriate for antimicrobial coated devices. [line 1167] This section specifies that While each of these types of combination products is subject both to the drug CGMPs and to the QS regulation, each example is used to focus on specific CGMP considerations relating to CGMP provisions specified in 21 CFR 4.4(b)., and.... [Line 1181] This discussion is intended to highlight only certain issues that a combination product might raise, and considerations for addressing them, relating to the CGMP provisions specified in 21 CFR 4.4(b). 17
18 ADVAMED COMMENTS Good Manufacturing Practice Requirements for Combination Products Line # Change Reason the ACC in accordance with 21 CFR 4.4(b)(2). While Manufacturer A must ensure that this operating system complies with the QS regulation, taking into account all of the issues raised by inclusion of the drug constituent part, this example focuses on considerations for complying with the drug CGMP provisions specified in 21 CFR 4.4(b)(2) which are different from those described in previous examples. Considering that the antimicrobial inhibitory function to inhibit bacterial growth.... a. 21 CFR Yield Calculations For the various yield calculations, overall yield is As Yield is also a measure of the active ingredients strength, and 21 CFR 210(a)(16) defines Strength as: (i) The concentration of the drug substance (for example, weight/weight, weight/volume, or unit dose/volume basis), and/or (ii) The potency, that is, the therapeutic activity of the drug product as indicated by appropriate laboratory tests or by adequately developed and controlled clinical data (expressed, for example, in terms of units by reference to a standard). As Potency is defined as the therapeutic activity of the drug product, measuring the IZ related functional antimicrobial activity by utilizing the ZOI test is an appropriate measurement technique. As the Theoretical and Actual Yield s concentration and potency are measured by the drug concentration sufficient for quantifiable functional Zone of Inhibition (ZOI) activity, the IZ Solution s antimicrobial drug concentration may be used as a surrogate (or alternative) method to measure the device s IZ level as well as the corresponding ZOI functionality FDA clearly describes cgmp differences for antimicrobial coatings which serve only to inhibit or prevent microbial colonization of the device [Federal Register Vol 78(14), January 22, 2013, p.4316, Comment 24 Response], which is significantly different than the Drug Coated Mesh example which treats infections. This difference clearly needs to be described and explained in the guidance document FDA states 1 that the calculation of yield: (S)hall be determined at the conclusion of each appropriate phase of manufacturing, processing, packaging, or holding'' for a drug product. This may provide valuable information and insight to the status of a manufacturing process at significant evaluation points, not just for the final product. In addition, (21 CFR) provides an important quality check both for a pharmaceutical production process as a whole and for individual unit operations of the process. It is important to account for any increase or decrease in expected yield of materials during the manufacturing process. When either occurs, it is important to conduct a prompt and thorough investigation. Appropriate manufacturing controls can help prevent deviations from expected process yield, which can be important to the success of manufacturing steps and to ensuring that the final product meets specifications. Any phase of the pharmaceutical process that is subject to potential component, in-process material, or product loss, due to physical or chemical means, should be evaluated with respect to actual and theoretical yield of these materials. Section does not apply to device constituent parts of combination products. Yield Calculations [21 CFR ] means actual yields and percentages of theoretical yield shall be determined at the 1 Federal Register Vol 78(14), January 22, 2013, p.4315, Comment 22 Response. 18
Combination products Updates Final FDA Guidance
Compliance Seminars Combination products Updates Final FDA Guidance Presented by Anna Lundén Webinar, March 8, 2017 Intentionally blank Compliance Seminars Our international course program for GMP professionals
More informationThe Device Side of Combination Products
The Device Side of Combination Products Technical and Regulatory Challenges in Life Cycle Management Bob Laughner Associate Director, Combination Products 04 May 2016 What are combination products? Combination
More information22 January Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, rm Rockville, MD 20852
22 January 2009 Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, rm. 1061 Rockville, MD 20852 SUBMISSION OF COMMENTS, DOCKET NO. FDA-2008-D-0559 Dear Sir or Madam:
More informationMarch 6, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852
701 Pennsylvania Avenue, NW Suite 800 Washington, D.C. 20004 2654 Tel: 202 783 8700 Fax: 202 783 8750 www.advamed.org March 6, 2017 Division of Dockets Management (HFA-305) Food and Drug Administration
More informationRE: Docket No. FDA 2017 N 0041: Agency Information Collection Activities; Proposed Collection; Comment Request; Safety Assurance Case
701 Pennsylvania Avenue, NW Suite 800 Washington, D.C. 20004 2654 Tel: 202 783 8700 Fax: 202 783 8750 www.advamed.org Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers
More information21 CFR Ch. I ( Edition) Personnel Design controls Identification Traceability.
Pt. 820 device together with an explanation of the basis for the estimate; (iv) Information describing the applicant s clinical experience with the device since the HDE was initially approved. This information
More informationCombination Products Part 4 Compliance and Implementation at multi-site Network
Combination Products Part 4 Compliance and Implementation at multi-site Network Vijay Damodaran Eli Lilly & Company September 27, 2017 Contents Key cgmp requirements for combination products How to perform
More informationPostmarketing Safety Reporting and cgmp Requirements for Combination Products. Katlin McKelvie Backfield November 2, 2017
Postmarketing Safety Reporting and cgmp Requirements for Combination Products Katlin McKelvie Backfield www.backfieldpllc.com November 2, 2017 Background: What is a Combination Product? Combination product:
More informationAAMI Quality Systems White Paper: Comparison of 21 CFR Part 820 to ISO 13485:2016 1
AAMI s White Paper Comparison of 21 CFR Part 820 to ISO 13485:2016 February 2017 AUTHORS Seb Clerkin, GMP Advisory Services Nicola Martin, Owner, Nicola Martin Consulting Jack Ward, Owner, Ward Sciences
More informationwas published. February 21, 2017
701 Pennsylvania Avenue, NW Suite 800 Washington, D.C. 20004 2654 Tel: 202 783 8700 Fax: 202 783 8750 www.advamed.org Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers
More informationEU and FDA GMP Regulations: Overview and Comparison
THE QUALITY ASSURANCE JOURNAL, VOL. 2, 55 60 (1997) EU and FDA GMP Regulations: Overview and Comparison The increasing emphasis on global supply of drug products, as well as starting materials and investigational
More informationRe: Docket No. FDA-2009-D-0179, Technical Considerations for Pen, Jet, and Related Injectors Intended for Use with Drugs and Biological Products
1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org July 27, 2009 Dockets Management Branch (HFA-305) Food and Drug Administration 5600 Fishers Lane, Rm. 1061 Rockville,
More informationCombination Products Workshop: CGMP and PMSR Requirements. GMP by the Sea August 28, Mark D. Kramer Regulatory Strategies, Inc.
Combination Products Workshop: CGMP and PMSR Requirements GMP by the Sea August 28, 2017 Mark D. Kramer Regulatory Strategies, Inc. 1 Definition of a Combination Product A combination of a drug, device
More informationPART 820 QUALITY SYSTEM REGULATION. 21 CFR Ch. I ( Edition)
814.126 (b) Withdrawal of IRB approval. A holder of an approved HDE shall notify FDA of any withdrawal of approval for the use of a HUD by a reviewing IRB within 5 working days after being notified of
More informationHot Topics in Drug Product Process Validation: A Reviewer s Perspective
Hot Topics in Drug Product Process Validation: A Reviewer s Perspective Colleen Thomas, Ph.D. Quality Assessment Lead (Acting) FDA/CDER/OPQ/OPF Division of Microbiology Assessment CASSS CMC Strategy Forum
More informationOctober 10, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852
October 10, 2017 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA 2017 D 2802: Chemistry, Manufacturing, and Controls
More informationDate: September 11, 2017 Reference No.: FDAA17008
Date: September 11, 2017 Reference No.: FDAA17008 VIA WEB Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm. 1061 Rockville, MD 20852 SUBJECT: Draft Standardization
More informationFood and Drug Administration, HHS Pt Sec Scope Definitions Quality system.
Food and Drug Administration, HHS Pt. 820 authorized designee. If, however, a physician in an emergency situation determines that approval from an IRB cannot be obtained in time to prevent serious harm
More information1201 Maryland Avenue SW, Suite 900, Washington, DC ,
1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org December 28, 2010 Dockets Management Branch (HFA-305) Food and Drug Administration 5600 Fishers Lane, Rm. 1061 Rockville,
More informationSeptember 12, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852
September 12, 2013 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 Re: : Draft Guidance for Industry on Pediatric Study Plans: Content
More informationISPE Annual Meeting 29 October 1 November 2017 San Diego, CA
Post Marketing Safety Reporting (PMSR) Challenges and Successful Practices for Combination Products Objective Session Goals Summary of the final rule Interpretation for combination products approved as
More informationCombination Products: A 40 Year Regulatory Evolution
The right people. The right solution. The first time. Combination Products: A 40 Year Regulatory Evolution Technological advances in healthcare products and the delivery of those products will continue
More informationRegulatory perspectives on CQAs, CPPs, and Risk Analyses for Combination Products.
Regulatory perspectives on CQAs, CPPs, and Risk Analyses for Combination Products. 3rd FDA/PQRI Conference on Advancing Product Quality March 22-24, 2017 TRACK #2 Achieving Drug Product Quality: Novel
More informationISPE Annual Meeting 29 October 1 November 2017 San Diego, CA. Combination Product Updates, Initiatives, and Case Studies. Steven B. Hertz, P.E.
Combination Product Updates, Initiatives, and Case Studies Steven B. Hertz, P.E. Consumer Safety Officer, FDA/CDER/OPQ Agenda 1: CP Overview 2: CDER Updates : CP Application Info : Case Studies 5: Summary
More informationCopyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.
Statutory Framework for Biologics Drugs Investigational Use Application IND Pre-Market Approval Applications 505(b)(1) NDA 505(b)(2) NDA 505(j) ANDA Over-the-Counter (OTC) Non- Rx Drugs Monograph Biologics
More informationMarch 9, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852
701 Pennsylvania Avenue, NW Suite 800 Washington, D.C. 20004 2654 Tel: 202 783 8700 Fax: 202 783 8750 www.advamed.org March 9, 2015 Division of Dockets Management (HFA-305) Food and Drug Administration
More informationGuidance for Industry and FDA Staff. Replacement Reagent and Instrument Family Policy
Guidance for Industry and FDA Staff Replacement Reagent and Instrument Family Policy Document issued on: December 11, 2003 This document supersedes Data for Commercialization of Original Equipment Manufacturers
More informationFDA-2011-N-0920; RIN 0910-AG36;
December 15, 2014 By Electronic Submission Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm. 1061 Rockville, MD 20852 Re: Current Good Manufacturing Practice
More informationGuidance for Industry Part 11, Electronic Records; Electronic Signatures Scope and Application
Guidance for Industry Part 11, Electronic Records; Electronic Signatures Scope and Application DRAFT GUIDANCE This guidance is being distributed for comment purposes only. Comments and suggestions regarding
More informationRe: Docket No. FDA-2000-D-0067: Medical Device Patient Labeling; Request for Comments; Public Workshop
701 Pennsylvania Avenue, NW Suite 800 Washington, D.C. 20004 2654 Tel: 202 783 8700 Fax: 202 783 8750 www.advamed.org October 30, 2015 Division of Dockets Management (HFA305) Food and Drug Administration
More informationOverview of comments received on 'Draft Guideline on manufacture of the finished dosage form'
14 July 2017 EMA/CHMP/QWP/104223/2016 Committee for Medicinal Products for Human Use (CHMP) Overview of comments received on 'Draft Guideline on manufacture of the finished dosage form' (EMA/CHMP/QWP/245074)
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 8 Inspections, Compliance, Enforcement, and Criminal Investigations Lupin Limited 5/7/09 Department of Health and Human Services Public Health Service Food and Drug Administration CENTER FOR
More informationBeth Hutchins, PhD PhRMA ICH Gene Therapy Discussion Group
ICH Considerations on General Principles to Address the Risk of Inadvertent Germline Integration of Gene Therapy Vectors and Current Topics on Gene Therapy in USA Beth Hutchins, PhD PhRMA ICH Gene Therapy
More informationDraft Guidance for Industry Development and Use of Risk Minimization Action Plans
Draft Guidance for Industry Development and Use of Risk Minimization Action Plans Docket Number [2004D-0188] Submitted to the U.S. Department of Health and Human Services Food and Drug Administration Center
More informationHarmonizing FDA Regulation and the Practice of Pharmacy: Challenges and Opportunities. Plus an update on PET Drug User Fees
Harmonizing FDA Regulation and the Practice of Pharmacy: Challenges and Opportunities Plus an update on PET Drug User Fees Michael Nazerias - Vice President, RA/QA PETNET Solutions, Inc. (a Siemens Company)
More informationCGMP and Postmarketing Safety Reporting Requirements for Combination Products
CGMP and Postmarketing Safety Reporting Requirements for Combination Products GMP by the Sea August 29, 2017 Mark D. Kramer Regulatory Strategies, Inc. 1 Definition of a Combination Product A combination
More informationNew Drug Product Impurities
Title Page Image - with courtesy of the FDA CDER original web site at www. cder.fda.gov/ New Drug Product Impurities IAGIM Scientific Committee Block JD; Holmann E ; West P NEW DRAFT GUIDANCE FDA Viewpoint
More informationDeciding When to Submit a 510(k) for a Change to an Existing Device Guidance for Industry and Food and Drug Administration Staff
Deciding When to Submit a 510(k) for a Change to an Existing Device Guidance for Industry and Food and Drug Administration Staff Document issued on October 25, 2017. The draft of this document was issued
More informationUpdates on Quality Metrics - Industry Perspectives Dan Snider Vice President, Research and Development Mylan Inc.
GPhA/FDA FALL TECHNICAL CONFERENCE Updates on Quality Metrics - Industry Perspectives Dan Snider Vice President, Research and Development Mylan Inc. Disclaimer This presentation contains a summary of the
More informationCANADA (HEALTH CANADA)
1 GMP GAZETTE TM May 2016 HPFBI CANADA (HEALTH CANADA) No updates NNHPD NHPs Final Monograph for Antiseptic Skin Cleanser Who`s Affected? Companies seeking NPN or DIN for topical antiseptic hand cleansers
More informationFINAL DOCUMENT. International Medical Device Regulators Forum. Medical Device Regulatory Audit Reports
FINAL DOCUMENT International Medical Device Regulators Forum Title: Authoring Group: Medical Device Regulatory Audit Reports IMDRF MDSAP Working Group Date: 2 October 2015 Toshiyoshi Tominaga, IMDRF Chair
More informationResponding to an FDA 483
Responding to an FDA 483 Jim Melancon VP, Associate General Counsel BioScrip, Inc. Marc Stranz, PharmD Healthcare Consultant Disclosure The speakers declare no conflicts of interest or financial interest
More informationU.S. Technical Advisory Group to ISO/Technical Committee 207 Clarification of Intent of ISO 14001
Committee Correspondence US SUB-TAG to ISO/TC/207/SC1 on Environmental Management Systems Administrator: Jennifer Admussen, ASQ Chair: Susan L.K. Briggs When originating or replying, please send copy to
More informationPharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act
Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance U.S. Department of Health and Human Services Food and Drug Administration Center for
More informationThe interface between Good Clinical Practice and Good Manufacturing Practice
1 The interface between Good Clinical Practice and Good Manufacturing Practice your partner in compliance 1 The interface between GCP and GMP Generally, studies are designed and planned by physicians who
More informationNovember 15, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane Room 1061 Rockville, MD 20852
November 15, 2013 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane Room 1061 Rockville, MD 20852 RE: Proposed Rule - Current Good Manufacturing Practice and Hazard
More informationCombination Products at US FDA
Multimodal Therapies for Brain Disorders: Session II Regulatory and Reimbursement Considerations Combination Products at US FDA Patricia Y. Love, MD, MBA Deputy Director Office of Combination Products,
More information"NOT FOR IMPLEMENTATION" GUIDANCE FOR INDUSTRY
"NOT FOR IMPLEMENTATION" GUIDANCE FOR INDUSTRY Modified Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo
More informationExperience with Health Canada s Approach for Post-Approval Changes. Kiran Krishnan Vice President US Regulatory Affairs September 2014
Experience with Health Canada s Approach for Post-Approval Changes Kiran Krishnan Vice President US Regulatory Affairs September 2014 Important Quotes to consider Dr. Janet Woodcock on desired state: A
More informationFDA s Final Rule on Medical Device Data Systems Signals Active Regulation of Data Communication Technologies
ADVISORY February 2011 FDA s Final Rule on Medical Device Data Systems Signals Active Regulation of Data Communication Technologies Contacts On February 15, 2011, the U.S. Food and Drug Administration
More informationGuidance for Industry
Guidance for Industry Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Quality DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions
More informationPlamena Entcheva-Dimitrov, PhD, RAC On-line Course.
Plamena Entcheva-Dimitrov, PhD, RAC On-line Course 1 The Preferred Regulatory Consulting content in this presentation is copyright protected under United States law and applicable international copyright
More information`HUMAN DRUG CGMP NOTES
`HUMAN DRUG CGMP NOTES (Volume 8, Number 3) September, 2000 (A Memo for FDA Personnel on Current Good Manufacturing Practice For Human Use Pharmaceuticals) Issued By: The Division of Manufacturing and
More informationAnnex A2. Guidance on Process Validation Scheme for Aseptically Processed Products
Annex A2 Guidance on Process Validation Scheme for Aseptically Processed Products 1 Table of content 1 PURPOSE... 3 2 SCOPE... 3 3 GENERAL INFORMATION... 3 4 INFORMATION NEEDED FOR ASEPTIC PROCESSES VALIDATION...
More informationSeite 1 von 13 (February 18, 1997) All NDA, ANDA, and AADA Holders Dear Sponsors: On November 30, 1995, the Scale-up and Post-Approval Changes Guidance for Immediate Release Products (SUPAC-IR) was published.
More informationDRAFT GUIDANCE. This guidance document is being distributed for comment purposes only. Document issued on: December 27, 2011
Draft Guidance for Industry and Food and Drug Administration Staff The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)] DRAFT GUIDANCE This guidance document is being
More informationSupplement FSSC & FSMA for Human Food FOOD SAFETY SYSTEM CERTIFICATION Supplement FSSC & FSMA for Human Food
Supplement FSSC & FSMA for Human Food FOOD SAFETY SYSTEM CERTIFICATION 22000 Supplement FSSC 22000 & FSMA for Human Food Version 1.0: September 2017 Supplement FSSC 22000 & FSMA for Human Food Contents
More informationQuality Agreements with CMO s. Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals
Quality Agreements with CMO s Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals FDA Guidance Contract Manufacturing Arrangements for Drugs: Quality
More informationUSP Chapter 823 USP 32 (old) vs. USP 35 (new)
USP Chapter 823 USP 32 (old) vs. USP 35 (new) Sally W. Schwarz, MS, BCNP Research Associate Professor of Radiology Washington University School of Medicine St. Louis, MO Why USP Chapter ? FDA has
More information) ) ) ) ) ) ) ) ) ) ) ) PCAOB Release No June 9, 2004
1666 K Street, N.W. Washington, DC 20006 Telephone: (202 207-9100 Facsimile: (202 862-8430 www.pcaobus.org RULE REGARDING CERTAIN TERMS USED IN AUDITING AND RELATED PROFESSIONAL PRACTICE STANDARDS PCAOB
More informationGUIDELINE FOR THE STABILITY TESTING
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 GUIDELINE FOR THE STABILITY TESTING OF NON-PRESCRIPTION (OTC)
More informationCorrespondence Between ISO 13485:2016 and 21 CFR Part 820 QMS Requirements
Correspondence Between and 21 CFR Part 820 QMS Requirements 10411 Corporate Drive, Suite 102, Pleasant Prairie, WI 53158 262.842.1250 262.842.1240 info@rcainc.com rcainc.com 2 4 Quality Management System
More informationGuidelines for Process Validation of Pharmaceutical Dosage Forms
Guidelines for Process Validation of Pharmaceutical Dosage Forms Version 2.1 Date issued 21/02/2010 Date of implementation 21/05/2010 31 August 2010 Page 1 of 20 Guidelines for Process Validation of Pharmaceutical
More informationIVT Laboratory Week Jerry Lanese. Ph.D. The Lanese Group, Inc The Lanese Group, Inc.
IVT Laboratory Week-2015 Jerry Lanese Ph.D. The Lanese Group, Inc. 1 Name Job What brought you here. 2 FDA interest in Quality Metrics What are Quality Metrics Quality metrics FDA will request The impact
More informationPurchasing Controls. FDA Small Business Regulatory Education for Industry (REdI) Conference Denver, Colorado May 13, 2015
Purchasing Controls FDA Small Business Regulatory Education for Industry (REdI) Conference Denver, Colorado May 13, 2015 LCDR Samantha Spindel, Ph.D. Premarket Programs Branch Division of Industry and
More informationGuidelines on procedures and data requirements for changes to approved biotherapeutic products. Proposed guidelines
0 0 0 0 WHO/PAC for BTPs_DRAFT/ Oct 0 ENGLISH ONLY Guidelines on procedures and data requirements for changes to approved biotherapeutic products Proposed guidelines NOTE: This document has been prepared
More informationEUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, 25 October 2005 EudraLex The Rules Governing Medicinal Products in the European Union Volume 4 EU
More informationWHO Prequalification of In Vitro Diagnostics Programme
P r e q u a l i f i c a t i o n T e a m - D i a g n o s t i c s Information for Manufacturers on the Manufacturing Site(s) Inspection (Assessment of the Quality Management System) WHO Prequalification
More informationIndustry Perspective on Manufacturing in Early Development
Industry Perspective on Manufacturing in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C. Eric Schmitt AbbVie IQ Drug Product Manufacturing Working Group August 2012 issue of Pharmaceutical
More informationICH Topic M 4 Q Location issues for Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality Questions and Answers
European Medicines Agency August 2003 CPMP/ICH/4680/02 ICH Topic M 4 Q Location issues for Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality Questions and Answers
More informationThere are risks and costs to a program of action. But they are far less than the long-range risks and costs of comfortable inaction
There are risks and costs to a program of action. But they are far less than the long-range risks and costs of comfortable inaction John F. Kennedy 12 May 1961 Annual Convention American for Democratic
More informationCopyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.
Statutory Framework for Devices Medical Devices Investigational Use Application IDE (21 CFR 812) Abbreviated IDE Exempt Pre-Market Approval Applications 510(k) Pre-marketing Notification (21 CFR 807(e))
More informationGuidance for Industry
Guidance for Industry Notification to FDA of Issues that May Result in a Prescription Drug or Biological Product Shortage DRAFT GUIDANCE This guidance document is being distributed for comment purposes
More informationISO /TS 29001:2010 SYSTEMKARAN ADVISER & INFORMATION CENTER SYSTEM KARAN ADVISER & INFORMATION CENTER
SYSTEM KARAN ADVISER & INFORMATION CENTER PETROLEUM, PETROCHEMICAL AND NATURAL GAS INDUSTRIES -- SECTOR-SPECIFIC QUALITY MANAGEMENT SYSTEMS -- REQUIREMENTS FOR PRODUCT AND SERVICE SUPPLY ORGANIZATIONS
More informationIndustry Perspective of US Combination Product Rule: Postmarket Safety Reporting Challenges and Proposed Solutions
Industry Perspective of US Combination Product Rule: Postmarket Safety Reporting Challenges and Proposed Solutions June 2017 By: Khaudeja Bano, Chair of the Combination Products Coalition (CPC) Postmarket
More informationEarly Development Best Practices for Stability- Regulatory Perspective
Early Development Best Practices for Stability- Regulatory Perspective IQ Workshop, Feb. 4-5, 2014, Washington, D.C. Ramesh Sood, Ph.D. Division Director (Acting) Office of New Drug Quality Assessment
More informationGUIDE TO INSPECTIONS OF QUALITY SYSTEMS
FOOD AND DRUG ADMINISTRATION GUIDE TO INSPECTIONS OF QUALITY SYSTEMS 1 1 August 1999 2 Guide to Inspections of Quality Systems This document was developed by the Quality System Inspections Reengineering
More informationEUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY. EudraLex. Volume 4
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Ref. Ares(2015)4234460-12/10/2015 Medicinal products quality, safety and efficacy Brussels, 12 October 2015 EudraLex Volume 4 EU Guidelines
More informationEuropean Medicines Agency Evaluation of Medicines for Human Use
European Medicines Agency Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BWP/49348/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL
More informationQuality Agreements and Managing Contract Supplier Quality
Quality Agreements and Managing Contract Supplier Quality American Society for Quality Lloyd Bailey November 3, 2005 Service Mark of The Dow Chemical Company TM Trademark of The Dow Chemical Company Abstract
More informationINTERNATIONAL RESEARCH JOURNAL OF PHARMACY ISSN Review Article
INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 8407 Review Article INTRODUCTION AND GENERAL OVERVIEW OF PHARMACEUTICAL PROCESS VALIDATION: A REVIEW Pandita Rachna* 1, Rana A C
More informationEPICOR, INCORPORATED QUALITY ASSURANCE MANUAL
EPICOR, INCORPORATED QUALITY ASSURANCE MANUAL Revision: 6 Date 05/18/09 EPICOR, INCORPORATED 1414 E. Linden Avenue P.O. Box 1608 Linden, NJ. 07036-0006 Tel. 1-908-925-0800 Fax 1-908-925-7795 Table of Contents:
More informationFDA > CDRH > CFR Title 21 Database Search
Seite 1 von 7 FDA Home Page CDRH Home Page Search A-Z Index 510 (k) Registration Listing Adverse Events PMA Classification CLIA CFR Title 21 Advisory Committees Assembler Recalls Guidance Standards New
More informationCell and Gene Therapy Medicinal Product Management Act (Draft) General Information
Cell and Gene Therapy Medicinal Product Management Act (Draft) General Information July 2017 At present there are still many diseases that cannot be cured by current medical technology and existing chemical
More informationTECHNICAL AND REGULATORY CONSIDERATIONS FOR PHARMACEUTICAL PRODUCT LIFECYCLE MANAGEMENT Q12
INTERNATIONAL CONCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED GUIDELINE TECHNICAL AND REGULATORY CONSIDERATIONS FOR PHARMACEUTICAL PRODUCT LIFECYCLE
More informationQuality Risk Management (ICH Q9): WHO Model for Sustainable Quality Medicines
Quality Risk Management (ICH Q9): WHO Model for Sustainable Quality Medicines Longe Sunday Anthony Head- Quality Assurance May & Baker Nigeria Plc. Pharmacentre, Ota, Nigeria eaglesconsult@gmail.com; Slonge@may-
More informationGuidance for Industry New Chemical Entity Exclusivity Determinations for Certain Fixed-Combination Drug Products
Guidance for Industry New Chemical Entity Exclusivity Determinations for Certain Fixed-Combination Drug Products DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments
More informationGLOBAL HEALTH SUPPLY CHAIN QUALITY ASSURANCE
GLOBAL HEALTH SUPPLY CHAIN QUALITY ASSURANCE Medical Device Product Questionnaire This questionnaire is used to collect information from vendors with regards to medical devices that fall in any of the
More informationGLOBAL HEALTH SUPPLY CHAIN QUALITY ASSURANCE
GLOBAL HEALTH SUPPLY CHAIN QUALITY ASSURANCE Finished Pharmaceutical Product Questionnaire This questionnaire is used to collect information from vendors with regards to finished pharmaceutical products
More informationOctober 13, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852
October 13, 2016 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 Re: Docket FDA-2016-D-1703; Draft Guidance for Industry and Food
More informationEnterprise and Industry Directorate-General European Commission B-1049 Brussels Belgium BY TO and
1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org 31 October 2008 Enterprise and Industry Directorate-General European Commission B-1049 Brussels Belgium BY EMAIL TO entr-gmp@ec.europa.eu
More informationLEGAL REQUIREMENTS FOR STABILITY
BY DR. A.V.PRABHU LEGAL REQUIREMENTS FOR STABILITY 21 CFR 211.166- STABILITY TESTING GMP To assess stability characteristics to determine storage conditions and expiration dates. Written stability program
More informationCGMP for Phase 1 INDs
CGMP for Phase 1 INDs Laurie P. Norwood Deputy Director Division of Manufacturing and Product Quality Office of Compliance and Biologics Quality Center for Biologics Evaluation and Research 1 Overview
More informationMedical Device Purchasing Controls Challenges of Compliance in a World Market June, 2013 OMTEC
Medical Device Purchasing Controls Challenges of Compliance in a World Market June, 2013 OMTEC - 2013 Quality Business Acceptance Activities 1 ..FDA Across the Globe.. 2 ..Warning Letters and FDA 483 update..
More informationZOLL Document Number: 90E0021 Page 6 of 50 QUALITY SYSTEM MANUAL ZOLL Document Number: 90E0021 Page 7 of 50 1 EXECUTIVE MANAGEMENT APPROVAL... 10 2 INTRODUCTION... 11 3 QUALITY SYSTEM... 12 3.1 QUALITY
More informationEU Annex 11 US FDA 211, 820, 11; other guidelines Orlando López 11-MAY-2011
Principle. a. This annex applies to all forms of computerised systems used as part of a GMP regulated activities. A computerised system is a set of software and hardware components which together fulfill
More informationResponses to Questions for SYSTEM 1E Process Monitoring and Validation Webinar
Responses to Questions for SYSTEM 1E Process Monitoring and Validation Webinar MONITORING THE SYSTEM 1E PROCESSOR Q: I want to confirm that there is no need for a Biological Indicator (BI) and that use
More informationInvestigator-Initiated INDs
Investigator-Initiated INDs Marjorie Small, RN, CCRC Office of Clinical Research 23 May 2011 PPHS/IRB Research Grand Rounds Outline of Presentation I. What is an IND? II. Code of Federal Regulations III.
More informationPharmacovigilance and the Generic Industry
Pharmacovigilance and the Generic Industry Presented by Joan Janulis, RAC Vice President Lachman Consultant Services Inc. 2015 Lachman Consultant Services, Inc. All rights reserved. Legal Notice The information
More informationMEDICAL DEVICE. Technical file.
MEDICAL DEVICE Technical file www.icaro-research.eu ICARO MDTF v1.0 1 Mar 2016 1. Do you plan to launch your medical device in Europe? If you re reading this, chances are good that you re considering introducing
More information